Osteoporosis Drugs Market in the APAC Region 2015-2019 is a new market research publication announced by Reportstack. Osteoporosis is a disease that reduces of the mass and density of bone, and results in increased risk of fracture. In this disease, the risks related to fracture increases because of the increased permeability of the bones. Often, there are no symptoms observed until the first fracture occurs. Increase in age, low body weight, low sex hormones or menopause, and smoking are some of the risk factors associated with this disease.
The analysts forecast that the Osteoporosis Drugs market in APAC to grow at a CAGR of 4.73 percent over the period 2014-2019.
Covered in this Report
The Osteoporosis Drugs market in APAC can be divided into two segments: Antiresorptives and Anabolics. This report covers the present scenario and the growth prospects of the Osteoporosis Drugs market in APAC for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various osteoporosis drugs that are available in the market.
The report, the Osteoporosis Drugs market in APAC 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Osteoporosis Drugs market in APAC landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
• Eli Lilly
Other Prominent Vendors
• F. Hoffmann La Roche
• Jiangsu Hengrui Medicine
• Pfizer Inc.
• Qingdao Chiatai Haier Pharmaceutical
To access full report with TOC, please visit Osteoporosis Drugs Market in the APAC Region 2015-2019.